On 23 June 2025, it was announced that people living with obesity will begin to access tirzepatide (Mounjaro) for weight loss in primary care settings across England.
However, this national announcement does not mean that prescriptions will be made available immediately to all eligible patients at GP practices.
Weight management services are commissioned locally by each area’s Integrated Care Board (ICB), meaning access to treatments like tirzepatide will differ between regions.
In Mid and South Essex, access to tirzepatide will initially be through specialist weight management services only.
At this time, tirzepatide will not be available via GP practices in Mid and South Essex. Access through primary care is not expected to begin until later in 2025.
This medication is prioritised for people with the highest clinical need and those living with obesity who also suffer from multiple obesity-related health conditions and stand to benefit the most from treatment.
👉 Find out more about eligibility and access to tirzepatide in Mid and South Essex by visiting the official NHS page:
Access to Tirzepatide for Weight Management – Mid and South Essex
